-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Holds the 2025 Policy and Objective Launch Conference
Category:
发布时间：2025-01-02
【概要描述】
With unwavering confidence in pursuing development and a steadfast commitment to hard work, we are forging a new chapter. On December 30–31, 2024, Shijiazhuang Sihua Pharmaceutical Group held its 2025 Policy and Objective Launch Conference, bringing together more than 200 mid- and senior-level managers from the Group’s various centers, business units, and subsidiaries, along with Group leaders Qu Jiguang, Su Xuejun, Wu Hengyao, and others, to jointly map out the Group’s ambitious blueprint for the year ahead. The conference was chaired by Group President Wu Hengyao.
With unwavering confidence in pursuing development and a steadfast commitment to “action” as the guiding principle, a new chapter is being opened. On December 30–31, 2024, Shijiazhuang Sihua Pharmaceutical Group held its 2025 Policy and Objective Launch Conference, bringing together more than 200 mid- and senior-level managers from the Group’s various centers, business units, and subsidiaries, along with Group leaders Qu Jiguang, Su Xuejun, Wu Hengyao, and others, to jointly map out the Group’s ambitious blueprint for the year ahead. The conference was chaired by Group President Wu Hengyao.
At the meeting, Group President Wu Hengyao first provided an overview of the preparation of the 2025 policy objectives.
During the policy and objective presentation session, 38 heads from the Group’s various centers, business units, and subsidiaries took to the stage one after another, passionately reporting on their 2024 performance in achieving set policies and objectives and on their comprehensive efforts to implement the 2025 targets. They highlighted concrete results, identified gaps, shared their strategic thinking, and outlined specific measures, thereby reaffirming their confidence and commitment to delivering outstanding performance next year. Following the presentations, Group leaders provided focused feedback and commentary on each presenter.
Amid warm applause, Qu Jiguang, Chairman of the Group’s Board of Directors, delivered a speech. He noted that, looking back on 2024, despite the myriad challenges and difficulties posed by unprecedented global and domestic changes in a century, all employees of Sihua Pharmaceutical have braved storms and risen to the occasion, relentlessly pursuing innovation, market expansion, and sustainable development. As a result, groundbreaking innovations have steadily accumulated and begun to yield significant results; the number of newly approved and submitted products has consistently remained at the forefront of the industry. In the competitive marketplace, the company’s flagship products—large-volume parenterals and bulk active pharmaceutical ingredients—have maintained their strong competitive edge, while the dual-circulation strategy—both domestic and international—has become even smoother, providing robust support for the company’s steady growth. Meanwhile, foundational management has grown more solid and effective, with enhanced system integration and cross-functional collaboration across production organization, quality certification, equipment upgrades and technological transformation, and logistics support, yielding impressive and continually improving performance in all these areas and powerfully propelling the company’s ascent into the ranks of the top 100 pharmaceutical enterprises.
Qu Jiguang pointed out that 2025 marks the final year of the Group’s implementation of the 14th Five-Year Plan and the year for formulating the 15th Five-Year Plan, meaning that the tasks ahead are heavier, the pressure is greater, and the challenges are more numerous. Therefore, it is of paramount importance to carefully plan and execute next year’s business operations. Over the course of two days, all departments and subsidiaries of the Group have collectively unveiled their 2025 guiding principles and objectives, with the aim of aligning thinking, grasping the overarching trends, converting positive factors from all fronts into concrete development results, and ensuring higher-quality implementation of the 2025 targets and goals—thereby laying a solid foundation for a strong start to the 15th Five-Year Plan. He emphasized that as long as our confidence remains unwavering, solutions will always outnumber difficulties.
To ensure the successful execution of the Group’s production and business operations in 2025 and beyond, Qu Jiguang made the following key directives: First, firmly grasp the critical links in operations, consolidate the leading position of marketing, and adopt a multi-pronged approach to transform innovation advantages into market and development strengths. Centered on market dynamics, product quality, cost control, and financial management, we must proactively plan and establish new, compliant business models that build upon our traditional strengths while aligning with the current market environment, thereby continuously enhancing the overall quality of the Group’s operations. Second, in the formulation business, prioritize quality improvement and efficiency enhancement, simultaneously pursuing both the expansion of established flagship products and the development of new offerings, seizing every opportunity for market access, and striving to convert innovation advantages into market advantages. We should broaden and elevate the scope and level of international certifications, actively engage in international cooperation and competition, promote the Group’s formulation exports as they set sail into global markets, and open up new markets and identify fresh business opportunities. Third, in the active pharmaceutical ingredient (API) and pharmaceutical packaging materials businesses, we must continually refine the product portfolios of Guangxiang Pharmaceutical, Guolong Pharmaceutical, and Bosheng Medical Devices, accelerate the commercialization of high-value-added, specialty new products, and pursue integrated development characterized by high-end positioning, intelligent manufacturing, and green practices. In doing so, we will further strengthen our cost and quality advantages, thereby bolstering the resilience and vitality of API development. Fourth, we must sustainably advance corporate R&D and innovation. We should steadfastly follow the “combination of generic and innovative” approach, closely integrating API–formulation synergy, and vigorously expedite the development and strategic deployment of pipelines for innovative drugs, improved innovative drugs, specialty generics, high-end complex formulations, as well as premium, high-end APIs and pharmaceutical packaging materials, ensuring that innovation outcomes continuously empower the company to move up the value chain toward the mid- to high-end segments. Fifth, we must continuously elevate the modernization of production and management processes, thereby solidifying the foundation for the Group’s industrial development. We must maintain rigorous quality risk management and workplace safety, while leveraging foundational projects and technological upgrades to proactively plan and implement digital transformation initiatives—starting with “5G-enabled workshops”—to set a benchmark for digital transformation and propel the Group’s new industrialization efforts to a new level.
Pragmatism is paramount; only through hard work and relentless striving can we achieve success. Attendees pledged to unite as one, pool our strengths, maintain unwavering confidence, put action first, and strive with vigor and determination. With renewed passion, a more pragmatic approach, and bolder strides, we will set out once again with unshakable resolve, ensuring the effective implementation of all key tasks and objectives for 2025 through solid, results-oriented work, and thereby forging a new chapter of high-quality development for the Group.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091